Medical implications from the crystal structure of a copper-containing amine oxidase complexed with the antidepressant drug tranylcypromine

FEBS Lett. 2004 Oct 22;576(3):301-5. doi: 10.1016/j.febslet.2004.09.031.

Abstract

The X-ray crystal structure of the copper-containing quinoprotein amine oxidase from E. coli has been determined in complex with the antidepressant drug tranylcypromine to 2.4 A resolution. The drug is a racemic mix of two enantiomers, but only one is seen bound to the enzyme. The other enantiomer is not acting as a substrate for the enzyme as no catalytic activity was detected when the enzyme was initially exposed to the drug. The inhibition of human copper amine oxidases could be a source of side-effects in its use as an antidepressant to inhibit the flavin-containing monoamine oxidases in the brain.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amine Oxidase (Copper-Containing) / chemistry*
  • Amine Oxidase (Copper-Containing) / metabolism
  • Antidepressive Agents / chemistry
  • Antidepressive Agents / metabolism
  • Binding Sites
  • Crystallography, X-Ray / methods
  • Escherichia coli / enzymology
  • Models, Molecular
  • Tranylcypromine / chemistry*
  • Tranylcypromine / metabolism

Substances

  • Antidepressive Agents
  • Tranylcypromine
  • Amine Oxidase (Copper-Containing)